Moderna Could Have a Big Problem on Its Hands
Investors could easily conclude that the worst is over for Moderna (NASDAQ: MRNA). The stock plunged more than 70% from its peak last summer. However, since March 7, 2020, Moderna's shares have rebounded by over 35%.
Renewed fears about COVID-19 have caused many to rethink their view of Moderna's prospects. However, any consideration of buying the vaccine stock needs to look beyond the near-term COVID-19 surges in China and Europe. And looking farther down the road, Moderna could have a big problem on its hands.
Image source: Getty Images.
Source Fool.com
